Inotuzumab ozogamicin regulatory update

Pfizer disclosed in its 1Q13 earnings that FDA granted Orphan Drug designation for its inotuzumab ozogamicin to treat acute lymphoblastic leukemia (ALL). The humanized mAb against CD22 linked to the ...